PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

PDS Biotech Announces Agreement with University of Georgia to License Novel Proteins for Versamune-based Universal Flu Vaccine

01 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

PDS Biotech Chief Medical Officer, Lauren V. Wood, to Present at the 2021 International Head and Neck Cancer Conference

27 Oct 2021 08:30:00 By Nasdaq GlobeNewswire

PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

21 Oct 2021 16:30:00 By Nasdaq GlobeNewswire

PDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination

21 Oct 2021 07:30:00 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast to Present Third-Quarter 2021 Financial Results

13 Oct 2021 16:30:00 By Nasdaq GlobeNewswire

PDS Biotechnology Welcomes Matthew Hill as Chief Financial Officer

06 Oct 2021 08:30:00 By Nasdaq GlobeNewswire

PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer

04 Oct 2021 08:30:00 By Nasdaq GlobeNewswire

PDS Biotechnology to Present at the Benzinga Healthcare Conference

27 Sep 2021 08:30:00 By Nasdaq GlobeNewswire

PDS Biotechnology to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

22 Sep 2021 08:30:01 By Nasdaq GlobeNewswire

PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Advanced Head and Neck Cancer

20 Sep 2021 08:30:00 By Nasdaq GlobeNewswire